Sector: MedicalABRAXIS BIOSCIENCE (NASDAQ: ABBI)
Ranking History
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 161 |
Technical : | 74 |
Performance : | 117 |
Overall: | 97 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 170 |
Technical : | 65 |
Performance : | 136 |
Overall: | 106 |
Number of Stocks: | 306 |
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 166 |
Technical : | 122 |
Performance : | 195 |
Overall: | 188 |
Number of Stocks: | 306 |
Headlines
- Abraxis Given China Approval for Cancer Drug ABRAXANE
Jul 15, 2008 06:24 PM | ABBI, AZN
- NASDAQ Technical Picture - Bulls Regain Momentum
Aug 09, 2007 02:15 AM | AAP, ABBI, ABI, ACF, AIRN, AOB
- Abraxis BioScience to Host R&D Investor Day and GlaxoSmithKline Gets New FDA Hycamtin OK
Jun 16, 2006 12:01 PM | ABBI, GSK, JNJ
- Pfizer Shares Rise After Viagra Patent Win and Glaxo HPV vaccine shows promise for women 26-55
Jun 06, 2006 11:01 AM | ABBI, GSK, PFE
- Abraxis BioScience Bolsters Manufacturing and Global Operational Expertise With Key Senior Executives and Wyeth Releases Study on Antidepressant
May 26, 2006 11:01 AM | ABBI, WYE
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
ABBI
|
Compare to S&P
|
| YTD |
-21.47 %
|
-22.42 %
|
| 4 Weeks |
-10.54 %
|
-7.07 %
|
| 12 Weeks |
0.75 %
|
-1.56 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -47.83 %
|
|
EPS Growth in Last Year: -33.33 %
|
|
Sales Growth in Last Quarter: -0.65 %
|
|
Sales Growth in Last Quarter: 18.62 %
|
|
